Targeted Expression of Growth Factors and Trophic Factors in the Retina and Retinal Pigmented Epithelium

The expression of vascular endothelial growth factor (VEGF) has been found to be associated with ocular neovascularization (NV) which is associated with disease processes leading to blindness, most notably diabetic retinopathy. The inventors have developed a line of transgenic mice expressing the VEGF gene that can be utilized in the evaluation of experimental drug therapies aimed at preventing or slowing the NV process in order to prevent blindness. This transgenic line of mice is a very useful model of retinal and subretinal neovascularization as it has many characteristics of clinical intraocular neovascularization and is very cheap and reliable, requiring no exogenous agents. Description (Set) Proposed Use (Set) This mouse model is ideal for the screening of experimental drugs targeting the VEGF gene and could be used in the research and development process for any company investigating compounds related to this gene.

Patent (Set) 6,479,729

Patents:
US 6,479,729

Inventor(s): Campochiaro, Peter A.

Type of Offer: Licensing



« More Medical Patents

---